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Abstract. The characterization of murine cell lines is of great 
importance in order to identify preclinical models that could 
resemble human diseases. Aberrant glycosylation includes the 
loss, excessive or novel expression of glycans and the appear-
ance of truncated structures. MB49 and MB49-I are currently 
the only two murine cell lines available for the development 
of preclinical bladder cancer models. The glycans Lewis 
X (LeX), Sialyl lewis X (SLeX) and Sialyl Tn (STn) have 
previously been associated with aggressiveness, dissemination 
and poor prognosis in human bladder cancer, additionally 
N-glycolyl GM3 (NGcGM3) is a neo-antigen expressed in 
many types of tumors; however, to the best of our knowledge, 
its expression has not previously been assessed in this type 
of cancer. Taking into account the relevance of glycans in 
tumor biology and considering that they can act as targets 
of therapies and biomarkers, the present study evaluated the 
expression of LeX, SLeX, STn and NGcGM3 in MB49 and 
MB49-I cells, in different growth conditions such as mono-
layer cultures, three-dimensional multicellular spheroids and 
mouse heterotopic and orthotopic tumors. The expression of 
LeX was not detected in either cell line, whereas SLeX was 
expressed in monolayers, spheroids and orthotopic tumors of 
both cell lines. STn was only identified in MB49 monolayers 
and spheroids. There are no reports concerning the expres-
sion of NGcGM3 in human or murine bladder cancer. In our 
hands, MB49 and MB49-I expressed this ganglioside in all the 
growth conditions evaluated. The assessment of its expression 
in cancer cell lines and patient tumors is of great importance, 
considering the relevance of this ganglioside in tumor biology. 
The data obtained by the present study demonstrates that 
glycan expression may be substantially altered depending 
on the growth conditions, highlighting the importance of the 
characterization of murine cancer models. To the best of our 
knowledge, the present study is the first to examine the expres-
sion of cancer-associated glycans, in the two murine cell lines 
available for the development of preclinical studies in bladder 
cancer.
Introduction
Bladder cancer accounts for approximately 165,000 deaths 
every year and is rated as the eleventh most common malig-
nancy worldwide (1). Urothelial carcinomas, which comprise 
90% of bladder tumors, are generally classified into three 
states: non-muscle-invasive, muscle-invasive, or metastatic (2) 
with a 5-year survival rates of less than 15% for those patients 
with metastatic disease (3). Depending on the stage of the 
tumor, treatment for bladder cancer consists in combinations 
of surgery, radiotherapy, chemotherapy, intravesical admin-
istration of BCG and, most recently, immune checkpoint 
inhibitors (4-9).
Cancer research has the constant challenge of developing 
preclinical models that recreate human disease allowing the 
evaluation and validation of anticancer therapies. The use of 
murine tumor cell lines and the development of tumors in 
immunocompetent mice appear as useful models for studies 
involving the microenvironment and the immune system, 
among others. In the particular case of bladder cancer, mouse 
models include carcinogen-induced tumors and orthotopic and 
heterotopic tumors developed by murine bladder cancer cell 
lines (10-12). There are two widely used murine tumor cell lines: 
MB49, developed from a 7,12-dimethylenzanthacene-induced 
bladder tumor in C57BL/6 mouse and MBT-2, developed from 
an FANFT-induced bladder tumor in C3H/He mouse (13,14). 
The latter was found to be contaminated with replicating type 
C retrovirus, turning this cell line in an unreliable model for 
immune assays (15,16). This leaves MB49 as virtually the 
only murine bladder cancer cell line used nowadays (11,12,14). 
Lodillinsky et al (17), generated a new bladder cancer cell line 
(MB49-I) by successive in vivo passages of primary tumor 
obtained by inoculating MB49 in C57BL/6 mice. MB49-I 
exhibited more invasive properties and its orthotopic inocu-
lation generated invasive tumors similar to invasive human 
bladder cancer, therefore making it an extremely interesting 
preclinical model. These two murine bladder cancer models 
Expression of bladder cancer‑associated 
glycans in murine tumor cell lines
MARINA ALBERTÓ1,  HECTOR ADRIÁN CUELLO1,  CYNTHIA ANABELLA GULINO1,  MARINA PIFANO1,   
DENISE BELGOROSKY2,  MARIANO ROLANDO GABRI1,  ANA MARÍA EIJÁN2  and  VALERIA INÉS SEGATORI1
1Laboratory of Molecular Oncology, Quilmes National University, Bernal B1876BXD;  
2Research Area, Instituto de Oncología Angel H. Roffo, Universidad de Buenos Aires, Buenos Aires 1417 DTB, Argentina
Received July 16, 2018;  Accepted December 17, 2018
DOI:  10.3892/ol.2019.9995
Correspondence to: Dr Valeria Inés Segatori, Laboratory of 
Molecular Oncology, Quilmes National University, 352 Roque Saenz 
Peña, Bernal B1876BXD, Argentina 
E-mail: valeria.segatori@unq.edu.ar
Key words: bladder cancer, glycans, murine models, MB49, MB49-I
ALBERTÓ et al:  EXPRESSION OF BLADDER CANCER GLYCANS IN MURINE TUMOR CELL LINES3142
have been characterized in various aspects (17-19); however, 
there is no information regarding their glycan expression 
profile.
Aberrant glycosylation is a phenomenon described in 
the malignant transformation and includes loss or excessive 
expression of certain glycans, appearance of incomplete or 
truncated structures and the appearance of novel glycans 
that can be associated to proteins or lipids (20,21). Changes 
in cellular glycoproteins and glycolipids have been proposed 
as a new cancer hallmark due to their association with 
malignant transformation and cancer progression (21). These 
glycoconjugates are involved in many biological processes 
and have a key role in several steps of tumor development and 
progression such as cell-cell adhesion, cell-matrix interac-
tion, inter and intracellular signaling, immune surveillance 
and many others (22). Taking into account that these glycans 
are differentially expressed in cancer over normal cells, 
they have been used as cancer biomarkers (23,24) and have 
been the target of numerous therapies for cancer treatment, 
including monoclonal antibodies against glycans, vaccines and 
glycan-directed CAR-T cells, among others (25-29).
Several glycans have been studied in human bladder cancer, 
among them the blood group antigen Lewis X (LeX) has been 
extensively validated as an urothelial carcinoma biomarker, 
as it can be detected in exfoliated urothelial cells (30-32). 
This glycan is expressed in bladder tumors regardless of its 
grade or stage; but is not commonly present in urothelial 
cells (31,32). Furthermore, it has been associated with inva-
sive and metastatic potential in this type of cancer (30,33). 
The sialylated variant of LeX, Sialyl Lewis X (SLeX), is also 
frequently expressed in tumor samples and human bladder 
cancer cell lines. This glycan has a key role in the recognition 
of selectins and it is involved in tumor cells dissemination. 
In particular, Fujii et al (34) reported SLeX involvement in 
E-selectin-mediated adhesion of urothelial cancer cells to 
endothelium. In addition, the expression of SLeX in samples 
from bladder carcinoma patients was found to strongly 
correlate with invasive and metastatic clinical outcome (35). 
Another relevant glycan in bladder cancer is Sialyl Tn (STn). 
STn is a truncated aberrant O-glycan that tends to appear in 
carcinoma mucins (20). Several reports have demonstrated 
the expression of this antigen in high grade muscle-invasive 
bladder tumors and its correlation with aggressiveness, poor 
prognosis and disease dissemination (36-38). Despite STn 
association with bladder cancer malignancy, its presence 
has been associated with better response to BCG therapy 
due to the induction of a stronger inflammatory response 
mediated by macrophages (39). The ganglioside N-glycolyl 
GM3 (NGcGM3) is a tumor neoantigen which is expressed 
in several types of cancer (40-45), and has been validated 
as a target for the development of cancer immunotherapy. 
However, there are no publications regarding this glycan in 
urothelial carcinoma, making it an interesting potential target 
or biomarker in this indication.
The development of a preclinical model in oncology 
involves the use of a murine cancer cell line with the ability to 
generate tumors in mice and to recreate the disease described in 
humans. This includes the analysis of the expression of glycans 
relevant in bladder cancer, which are also targets of validated 
therapies in other indications (10-12). Glycan target-directed 
immunotherapies are a good example, since the validation of 
these therapies needs immunocompetent cancer mouse models, 
as the use of human cancer cell lines in immunosupressed 
mice is not suitable (26). MB49 and MB49-I are capable of 
developing tumors in syngeneic mice and possess biological 
characteristics similar to human bladder cancer (17), but there 
is no information regarding bladder cancer-associated glycans 
expression in these cell lines.
Taking into account the relevance of glycosylated targets 
in cancer therapy and the lack of information regarding this 
topic in murine bladder cancer models, the aim of this work 
was to characterize the expression of bladder cancer-associ-
ated glycans LeX, SLeX, STn, and NGcGM3 as part of the 
glycophenotype of most significant murine bladder cancer 
cell lines MB49 and MB49-I, including monolayer cultures, 
three-dimensional multicellular spheroids, and heterotopic 
and orthotopic tumors developed from these cell lines.
Materials and methods
Tumor cells and culture conditions. Murine bladder cancer 
cell line MB49 was obtained from Dr E.C. Lattime, Thomas 
Jefferson University, Philadelphia, USA. MB49-I was gener-
ated by Lodillinsky et al (17), as described previously. Human 
bladder cancer cell line T24 was purchased in ATCC (ATCC® 
HTB-4™). Cell lines MB49, MB49-I and T24 were grown 
in RPMI medium (Gibco; Thermo Fisher Scientific, Inc., 
Waltham, MA, USA) supplemented with 10% heat-inactivated 
fetal bovine serum (FBS) (Gibco; Thermo Fisher Scientific, 
Inc.), 2 mM glutamine and 80 µg/ml gentamicin at 37˚C in 
5% CO2 atmosphere. Cell cultures were routinely subcultured 
twice a week by tripsinization using standard procedures.
Animals. Pathogen-free C57BL/6J mice approximately 
10 weeks-old, with an average weight of 25 g, were obtained 
from the Animal Care Division of UNLP (La Plata, Argentina). 
Up to 5 mice per cage were kept with water and food ad libitum 
in the animal house facility at Quilmes National University. 
All protocols were approved by the Institutional Committee 
for the Care and Use of Laboratory Animals at Quilmes 
National University.
Three‑dimensional multicellular tumor spheroids growth. 
Spheroids were prepared using a modified protocol based on 
the liquid overlay technique described by Yuhas et al (46) Cell 
culture 96-well plates were underlayed with 1.5% agarose (GE 
Healthcare, Chicago, IL, USA) in RPMI-10% FBS. Spheroids 
were initiated by inoculating 10,000 or 20,000 cells in 
RPMI-10% FBS, followed by cycles of agitation. The medium 
was replaced once during the growth of the spheroids. At 
day 14 the spheroids were fixed in 4% paraformaldehyde, 
centrifuged and resuspended in 2% agarose. This material was 
embedded in paraffin and processed for histology.
Flow cytometry assay (FACS). Tumor cells were harvested 
with trypsin-EDTA solution, resuspended in serum-free 
RPMI, and 1x106 cells per sample were incubated with glycan's 
specific monoclonal antibodies (mAbs), biotinylated lectins, 
isotype control or PBS for 30 min at 4˚C or room tempera-
ture according to the mAb datasheet. The mAbs used were: 
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NeuGcGM3 (mouse anti-mouse 14F7, 20 µg/ml; produced 
by the Center of Molecular Immunology, La Habana, Cuba); 
SLeX (mouse anti-mouse SNH3, 20 µg/ml; cat. no: 012-15211; 
Wako Pure Chemical Industries, Ltd., Osaka, Japan); LeX 
(mouse anti-mouse P12, 1/100; cat. no: AB74035; Abcam, 
Cambridge, MA, USA); STn (mouse anti-mouse B72.3 TAG-72, 
20 µg/ml; cat. no: sc-20042; Santa Cruz Biotechnology, Inc., 
Dallas, TX, USA); Mouse IgG1 isotype control (2 ng/ml; cat. 
no: MA5‑14453; Thermo Fisher Scientific, Inc.), Mouse IgM 
isotype control (2 ng/ml; cat. no: X0942; Agilent Technologies, 
Inc., Santa Clara, CA, USA) The lectins used were: Mal 
II and SNA, (1/100; cat. nos: B-1265 and B1305; Vector 
Laboratories, Inc., Burlingame, CA, USA). Then, tumor cells 
were washed with PBS and incubated with Polyclonal Goat 
Anti-Mouse Phycoerythrin (PE) labeled anti-mouse immuno-
globulins (5 ug/ml, cat. no: R048001; Agilent Technologies, 
Inc.) or Fuorescein Streptavidin (cat. no: SA-5001; Vector 
Laboratories, Inc.) for 30 min at 4˚C. Acquisition was achieved 
by a FACSCalibur flow cytometer (BD Biosciences, Franklin 
Lakes, NJ, USA) and analyzed by the FlowJo® software.
Immunohistochemistry (IHC). Staining of sections consisted 
of antigen retrieval with sodium citrate followed by incuba-
tion with blocking serum (Vectastain Elite ABC HRP kit 
(Peroxidase, Universal, cat. no: PK-6200; Vector Laboratories, 
Inc.). Sections were incubated with specific mAbs or PBS as 
negative control for 30 min. The mAbs used were: NeuGcGM3 
(mouse anti-mouse 14F7, 25 µg/ml; produced by the Center 
of Molecular Immunology, La Habana, Cuba); SLeX (mouse 
anti-mouse SNH3, 5 µg/ml; cat. no: 012-15211; Wako Pure 
Chemical Industries, Ltd.); LeX (mouse anti-mouse P12, 1/40; 
cat. no: AB74035; Abcam); STn (mouse anti-mouse B72.3 
TAG-72, 4 µg/ml; cat. no: sc-20042; Santa Cruz Biotechnology, 
Inc.). Sections were incubated with biotinylated secondary Ab 
(Vectastain Elite ABC HRP Kit (Peroxidase, Universal; cat. 
no: PK-6200; Vector Laboratories, Inc.) for 1 h, followed by 
peroxidase-conjugated avidin-biotin complex for 1 h. Bound 
antibodies were detected by incubation with diaminobenzi-
dine substrate and tumor sections were then counterstained 
with haematoxylin. Results obtained by IHC were semiquan-
titatively evaluated, and scored by two independent observers. 
Specific staining intensity was compared to its negative control 
and graded as intense, moderate, low or negative.
Heterotopic tumor growth. At day 0, groups of at least three 
mice were inoculated subcutaneously in the right flank with 
2x105 viable MB49 or MB49-I cells per mouse in 0.2 ml of 
RPMI. Primary tumor development was monitored by palpation 
and tumors were measured periodically with a caliper. Tumor 
volume was calculated by the formula: 0.52 x width2 x length. 
Animals were sacrificed by cervical dislocation when subcu-
taneous tumor volume reached 2,000 mm3. Tumors obtained 
were removed, fixed with formalin, embedded in paraffin and 
processed for histology as previously described.
Orthotopic tumor growth. Orthotopic tumors were developed 
as described in Lodillinsky et al (17). Briefly, a 24 gauge 
polytetrafluoroethylene coated catheter was introduced into the 
bladder lumen through the urethra of anesthetized C57BL/6J 
female mice [intraperitoneal injection of ketamine (70 mg/kg) 
plus xylazine (5 mg/kg)]. 2x104 cells from subconfluent MB49 
or MB49-I monolayers were instilled in 100 µl RPMI. Mice 
were monitored twice weekly for hematuria (blood in urine 
during bladder palpation) and by bladder palpation. Two weeks 
after tumor cell inoculation the animals were sacrificed by 
cervical dislocation (17). Tumors obtained were removed, 
fixed with formalin, embedded in paraffin and processed for 
histology as previously described.
Statistical analysis. Results described in this work are 
expressed as median with interquartile range. Statistical 
analyses were carried out using GraphPad Prism v.6.0 statis-
tical software (GraphPad, Inc., La Jolla, CA, USA). Normal 
distribution of data was evaluated using the D'Agostino and 
Pearson omnibus normality test, for comparisons between 
experimental groups, we used Mann Whitney test. P<0.05 was 
considered to indicate a statistically significant difference.
Results
Glycans expression in cell line monolayers. The first approach 
in the characterization of selected glycans expression of the 
murine bladder cancer cell lines was the analysis of the binding 
of two lectins that recognize sialic acids bound to glycoconju-
gates. Mal II is a lectin derived from Maackia amurensis and 
has affinity for α2,3-linked sialic acid. This type of linkage 
is associated with the presence of SLeX (Fig. 1). SNA lectin 
derives from Sambucus nigra and binds to α2,6-linked sialic 
acid, present in STn (Fig. 1). When the binding of Mal II was 
evaluated by FACS, MB49 showed a higher fluorescence 
intensity than MB49-I, indicating that it possesses more sialic 
acids with α2,3 linkage (Fig. 2A). Same results were obtained 
when SNA was evaluated, showing more binding to MB49 
cells in relation to MB49-I (Fig. 2B).
The expression of the glycans LeX, SLeX, STn and 
NGcGM3 (Fig. 1) in the murine bladder cancer cell lines MB49 
and MB49-I was then evaluated by FACS. Representative 
dot plots of the percentage of positive cells of these four 
glycans for MB49 and MB49-I cells respectively, are shown 
in Fig. 3A and B. The percentage of antigen expression was 
considered ‘high’ when more than 50% of positive events were 
observed, ‘moderate’ when it was measured between 30 to 
50% and ‘low’ when it was less than 30% but more than 10%. 
The glycan LeX was not detected in any of the cell lines. On 
the other hand, both cell lines were positive for SLeX, with 
a high expression displayed in MB49 and a moderate one in 
MB49‑I. Median fluorescence intensity values (MFI) were 
47.42 and 8.99 for MB49 and MB49-I respectively. MB49 also 
exhibited a high expression of STn, showing a MFI of 14.36, 
while MB49-I was considered negative for this antigen (MFI: 
0.2). The results of the evaluation of SLex and STn by FACS 
were in accordance with the results obtained in the lectins 
binding assay. In relation to NGcGM3, MB49 showed low 
expression of this ganglioside, while MB49-I was moderately 
positive.
Glycan expression in three‑dimensional spheroids. 
Three-dimensional spheroids were analyzed by IHC. 
Intensity of color developed by the staining with each 
mAb was compared to its negative control assigning one 
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of the four scores described in the Materials and Methods 
section. In the case of tumors spheroids, the expression of 
the glycan LeX was considered negative in both cell lines, 
while SLeX showed an intense staining in MB49 spheroids 
and a moderate one in MB49-I. The antigen STn had a 
moderate expression but only in MB49 spheroids. On the 
other hand, the ganglioside NGcGM3 was highly expressed 
in spheroids derived from both cell lines. Representative 
photos are presented in Fig. 4A and B.
Glycan expression in tumors. Regarding heterotopic tumors, 
NGcGM3 was the only glycan that was intensely expressed 
in both MB49 and MB49-I. None of the three other glycans 
were detected in this type of tumors (Fig. 5A and B). On the 
other hand, the analysis of glycans expression in orthotopic 
tumors revealed an intense staining of SLeX in MB49 tumors 
and a moderate one in MB49-I. Both MB49 and MB49-I 
tumors highly expressed NGcGM3; but STn and LeX were not 
detected whatsoever (Fig. 5C and D).
NGcGM3 expression in T24 human bladder cancer cells. 
Taking into account the obtained results regarding the expres-
sion of NGcGM3 in murine cell lines and the fact that there 
are no reports of this glycan in human bladder cancer, we 
decided to evaluate the expression of this ganglioside in the 
cell line T24. NGcGM3 expression was analyzed either in cell 
monolayer or in three-dimensional tumor spheroids by FACS 
or IHC respectively. NGcGM3 was moderately expressed in 
this cell line (Fig. 6A) with a MFI of 6.47. Accordingly, spher-
oids derived from T24 cell line revealed an intense staining of 
this glycan (Fig. 6B).
Discussion
Glycans are targets of many approved and developing anticancer 
treatments and thus it is important to have preclinical models 
that express these antigens recreating human disease in order 
to evaluate and validate anticancer therapies. Tumor cell lines 
have been widely used for in vitro studies, but this approach 
does not resemble the 3D properties of tumors in physiological 
conditions, including interactions with immune cells and tumor 
microenvironment (3,47). A first step to shorten the distance 
between in vitro and in vivo studies is the three-dimensional 
multicellular tumor spheroid model, where cells adhere to each 
other forming a spherical cell mass with different cell popu-
lations and no artificial substrate for cell attachment. Tumor 
spheroids generally have a population of proliferating cells in 
the outer region and a group of quiescent and necrotic cells in 
the central zone; a phenomenon that occurs due to the existent 
Figure 2. Evaluation of lectins (A) Mal II and (B) SNA binding to MB49 
and MB49‑I cell lines by FACS. Results correspond to median fluorescence 
intensity relative to negative control (PBS) of five independent experiments. 
Data are expressed as median with interquartile range; Mann Whitney test 
*P<0.05. FACS, fluorescence activated cell sorting; MFI, Median fluores-
cence intensity values.
Figure 1. Monosaccharide structure of the glycans analyzed in the present 
study. LeX, Lewis X; SLeX, Sialyl Lewis X; STn, Sialyl Tn; NGcGM3, 
N-glycolyl GM3. The letter R represents any structure of a protein or lipid.
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Figure 4. Evaluation of glycan expression in (A) MB49 and (B) MB49-I three-dimensional tumor spheroids by IHC. Photos are representative of at least three 
experiments. Original magnification, x400.
Figure 3. Evaluation of glycan expression in (A) MB49 and (B) MB49-I cell lines by FACS. The percentage of positive cells for each glycan is indicated in the 
graphs. Representative dot plots of at least three independent experiments. FSC-H, forward side scatter.
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gradient of nutrients and oxygen (3,48,49). Thus, the growth of 
tumor spheroids can better recreate tumor cellular heterogeneity, 
cell-cell interactions and spatial structure, with the advantage of 
being a low cost and short duration assay (3,47,49).
Regarding in vivo studies, the development of heterotopic 
tumors in mice, mainly subcutaneous tumors, has been 
extensively used in cancer research due to its many advan-
tages, such as easy manipulation and the ability to monitor 
tumor growth. However, it is well reported that this surrogate 
microenvironment affects the tumor in a different manner 
compared to the tumor growing in its orthotopic site (50-52). 
Hence, the importance of characterizing each model.
Figure 5. Evaluation of glycan expression in tumors by IHC. (A) MB49 heterotopic tumors; (B) MB49-I heterotopic tumors; (C) MB49 orthotopic tumors; 
(D) MB49‑I orthotopic tumors. Photos are representative of at least three experiments. Original magnification, x400.
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The use of murine cancer cell lines and the growth of 
tumors in immunocompetent mice allow the study of the effect 
of the microenvironment and the immune system on tumor 
progression, among other advantages. In the case of bladder 
cancer, MB49 and MB49-I are the only murine tumor cell 
lines available, thus it is essential to better characterize them 
in order to describe and establish their in vitro and in vivo 
behavior. Taking into account the importance of glycans in 
tumor biology, and considering they can act as targets of 
therapies and biomarkers, we evaluated the expression of LeX, 
SLeX, STn and NGcGM3 in MB49 and MB49-I, including 
monolayer cultures, three-dimensional multicellular spher-
oids, heterotopic and orthotopic tumors developed from these 
cell lines.
The glycan LeX has been proposed as a biomarker of 
urothelial carcinoma (30-32). Nevertheless, the evaluation of 
LeX expression in both cell lines revealed no detectable pres-
ence of this antigen in either monolayers or spheroids nor in 
tumors; rendering this model useless for the study of the role 
of this glycan in bladder cancer biology (Table I). Another 
relevant glycan evaluated was SLeX, which has been associ-
ated with invasiveness and metastatic capacity in various 
types of cancer, including bladder cancer (20,25,34,35,53). Its 
presence was detected in both cell lines, and also in spheroids 
and orthotopic tumors. No expression was found in hetero-
topic tumors whatsoever. MB49 and MB49-I appear as useful 
models for the study of SLeX in bladder cancer, both in vitro, 
including the spheroids model, and in vivo, with the develop-
ment of orthotopic tumors (Table I). The neo-antigen STn 
was also associated with aggressiveness and poor prognosis 
in human bladder cancer (36-38). The presence of this glycan 
was only confirmed in MB49 monolayers and spheroids. Both 
heterotopic and orthotopic tumors derived from this cell line 
lost the expression of this antigen (Table IA), confirming the 
importance of the role of the microenvironment in the glyco-
phenotype. In relation to MB49-I, it appears that during the 
development of this cell line the expression of STn was not 
essential in tumor malignancy and was lost (Table IB). Even 
though this antigen is present in more than 80% of human 
carcinomas, including urothelial carcinomas (54), there 
are no reports regarding its expression in tumor cell lines. 
Furthermore, the majority of the models used to study this 
antigen include the induced overexpression of the enzymes 
involved in its synthesis (38,39,55-57). Therefore, MB49 cell 
line maintained in vitro either as a monolayer or as spheroids, 
appear to be valuable models for the in vitro study of STn. As 
mentioned before, three-dimensional multicellular spheroids 
can better recreate tumor cellular growth condition in vitro. 
Considering our results regarding STn expression, tumor 
spheroids in particular seem to be a reliable tumor growth 
model for analyzing the relevance of this glycan in bladder 
cancer.
N-glycolylneuraminic acid (NeuGc) is not found in human 
tissues due to a deletion in the CMP-N-acetylneuraminic 
acid hydroxylase (CMAH) gene. CMAH is the enzyme 
responsible for the synthesis of this sialic acid (58,59) which 
is then incorporated to different membrane glycoconju-
gates, such as the ganglioside NGcGM3, by the action of 
Figure 6. Evaluation of NGcGM3 expression in (A) T24 cell line by FACS; Representative dot plots of at least three independent experiments. (B) T24 
three‑dimensional tumor spheroids by IHC. Photos are representative of at least three experiments. Original magnification, x400. The percentage of positive 
cells for each glycan is indicated in the graphs. FSC-H, forward side scatter.
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sialyltransferases. Even though human tissues do not express 
NGcGM3, it is considered a tumor neo-antigen in many 
types of cancer (40-45). It is proposed that tumor cells can 
incorporate NeuGc from dietary sources (60) due to the 
overexpression of the sialic acid transporter sialin under 
hypoxic conditions (61). There are no reports concerning the 
expression of NGcGM3 in human or murine bladder cancer. 
In our hands, MB49 and MB49-I expressed this ganglioside 
in all the growth conditions evaluated (Table I). Moreover, 
the evaluation of the presence of this antigen in the human 
bladder cancer cell line T24 and its spheroids turned out to 
be positive. The assessment of the expression of NGcGM3 
in human bladder cancer cell lines and patient's tumors is of 
great importance, considering the relevance of this ganglio-
side in tumor biology, its differential expression in tumor cells 
over normal tissues and the existence of NGcGM3-directed 
therapies (62,63).
The characterization of murine cell lines is of great 
importance so as to find models that resemble human diseases. 
MB49 and MB49-I are currently the only two murine cell lines 
available for the development of preclinical bladder cancer 
models. In this work, we demonstrate that glycan expression 
may substantially change depending on growth conditions. 
The three-dimensional tumor spheroid model showed a 
pattern of glycan expression similar to the observed in cell line 
monolayers. On the other hand, heterotopic tumors, although 
useful for their simplicity in comparison with orthotopic ones, 
do not satisfactorily recreate the original microenvironment, 
thus affecting the tumor expression of certain glycans. Among 
in vivo models, the setting that better resembled tumor glycan 
expression for these cell lines were the orthotopic tumors, and 
we consider that it should be the first choice for in vivo studies 
when possible. This is the first work that reports the expres-
sion of relevant bladder cancer-associated glycans in the two 
murine cell lines available for the development of preclinical 
studies in bladder cancer. Although studies of the biological 
role of these glycans in MB49 and MB49-I are necessary to 
confirm their similarity to human bladder cancer, this work 
also provides useful information when choosing a model for 
the evaluation and validation of anticancer therapies based on 
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Table I. Glycan expression in MB49 and MB49-I cell lines in different growth conditions. 
A, MB49
Antigen Monolayers Tumor spheroids Heterotopic tumors Orthotopic tumors
LeX Negative Negative Negative Negative
SLeX High Intense Negative Intense
STn High Moderate Negative Negative
NGcGM3 Low Intense Intense Intense
B, MB49-I
Antigen Monolayers Tumor spheroids Heterotopic tumors Orthotopic tumors
LeX Negative Negative Negative Negative
SLeX Moderate Moderate Negative Moderate
STn Negative Negative Negative Negative
NGcGM3 Medium Intense Intense Intense 
LeX, Lewis X; SLeX, Sialyl Lewis X; STn, Sialyl Tn; NGcGM3, N-glycolyl GM3.
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